Inventor · Lagrangeville, NY, US

Daniel Dix

48Patents
22h-index
22Co-inventors
85Inventor score

Filing activity: Aug 17, 2005 → Oct 23, 2024

Most-cited inventions

PatentTitleAreaCited byStatus
US8092803B2 VEGF antagonist formulations for intravitreal administration Chemistry; Metallurgy 103 Active
US7608261B2 VEGF antagonist formulations suitable for intravitreal administration Chemistry; Metallurgy 87 Active
US7807164B2 Lyophilized VEGF antagonist formulations for intravitreal administration Chemistry; Metallurgy 60 Active
US10464992B2 VEGF antagonist formulations suitable for intravitreal administration Chemistry; Metallurgy 59 Active
US8110546B2 VEGF antagonist formulations Emerging Cross-Sectional Technologies 58 Active
US9340594B2 VEGF antagonist formulations for intravitreal administration Chemistry; Metallurgy 56 Active
US8481046B2 VEGF antagonist formulations for intravitreal administration Chemistry; Metallurgy 55 Active
US10406226B2 Method of manufacturing VEGF antagonist fusion proteins Emerging Cross-Sectional Technologies 55 Active
US9580489B2 VEGF antagonist formulations suitable for intravitreal administration Chemistry; Metallurgy 49 Active
US9416167B2 Stable liquid formulations of dimer VEGF antagonists Emerging Cross-Sectional Technologies 48 Active
US8802107B2 VEGF antagonist formulations for intravitreal administration Chemistry; Metallurgy 48 Active
US9511140B2 Stable VEGF antagonist formulations Emerging Cross-Sectional Technologies 47 Active
US8404638B2 Dimer VEGF antagonist formulations Emerging Cross-Sectional Technologies 47 Active
US8710004B2 Stable liquid VEGF antagonist formulations Emerging Cross-Sectional Technologies 46 Active
US8921316B2 Stable liquid VEGF antagonist formulations Emerging Cross-Sectional Technologies 46 Active
US8945559B2 Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies Chemistry; Metallurgy 44 Active
US9636400B2 VEGF specific fusion protein antagonist formulations Emerging Cross-Sectional Technologies 43 Active
US9914763B2 VEGF antagonist formulations suitable for intravitreal administration Chemistry; Metallurgy 41 Active
US10400025B2 VEGF antagonist formulations suitable for intravitreal administration Chemistry; Metallurgy 40 Active
US9173880B2 Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies Chemistry; Metallurgy 32 Active
US8795669B2 Stabilized formulations containing anti-PCSK9 antibodies Chemistry; Metallurgy 29 Active
US9402898B2 Stabilized formulations containing anti-Ang2 antibodies Chemistry; Metallurgy 22 Active
US9238692B2 Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies Chemistry; Metallurgy 22 Active
US9193801B2 Stabilized formulations containing anti-PCSK9 antibodies Chemistry; Metallurgy 20 Active
US10435473B2 Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies Chemistry; Metallurgy 13 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.